Pulmatrix Reports Q1 2026 Financial Results, Faces Operational Challenges Amid Merger with Eos

Pulmatrix, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.2 million, a decrease from a net loss of $1.8 million in the same period of 2025. The company's total operating expenses for the quarter were $1.3 million, down from $1.8 million year-over-year, primarily due to reduced general and administrative costs. Research and development expenses remained minimal at $3,000, compared to $19,000 in the prior year, as the company has paused clinical development while exploring options to license or monetize its assets.

In terms of liquidity, Pulmatrix had $3.3 million in cash and cash equivalents and $0.7 million in restricted cash as of March 31, 2026. The company raised $1 million through the sale of Series B Convertible Preferred Stock during the quarter, which is part of a broader strategy to secure funding amid ongoing operational challenges. The total cash position reflects a decrease from $4.1 million at the end of 2025, indicating a need for additional financing to support future operations.

Strategically, Pulmatrix is in the process of merging with Eos SENOLYTIX, Inc., a move that could significantly alter its operational landscape. The merger agreement, signed on March 26, 2026, is subject to stockholder approval and other customary closing conditions. If completed, Eos will become a wholly owned subsidiary of Pulmatrix, with Eos stockholders expected to own approximately 94% of the combined entity. The success of this merger is critical for Pulmatrix, as management has indicated that failure to consummate the deal may lead to a consideration of dissolution and liquidation.

Operationally, the company has not reported significant changes in customer counts or product adoption rates, as its clinical development activities are currently on hold. The focus remains on leveraging its proprietary iSPERSE™ technology for inhaled therapeutic products targeting migraine and respiratory diseases. The company has indicated that it will need to secure substantial additional funding to continue development of its product candidates, which include PUR3100 for acute migraine treatment and PUR1800 for chronic obstructive pulmonary disease.

Looking ahead, Pulmatrix's future operations are highly contingent on the successful completion of the merger with Eos and the ability to secure additional funding. The company anticipates continued operating losses as it navigates the complexities of the merger and seeks to advance its product pipeline. Management has expressed that without the merger's success, there is substantial doubt about the company's ability to continue as a going concern within the next year.